LA JOLLA PHARMACEUTICAL CO Form 8-K March 11, 2004 Table of Contents

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

#### FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE

#### **SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): March 11, 2004

## La Jolla Pharmaceutical Company

(Exact I	Name of Registrant as Specified in Cl	harter)
Delaware	0-24274	33-0361285
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
6455 Nancy Ridge Drive, San Diego,	California	92121
(Address of Principal Executive Offices)		(Zip Code)
Registrant s telephone number, including area code:		(858) 452-6600
	N/A	

(Former Name or Former Address, if Changed Since Last Report)

## Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

# TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. SIGNATURES EXHIBIT INDEX EXHIBIT 99.1

#### Table of Contents

#### Item 5. Other Events and Required FD Disclosure.

On March 11, 2004, the Company issued a press release that contained additional data from the Company's Phase 3 and 2/3 clinical trials of Riquent<sup>®</sup>. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

#### Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) *Exhibits*. The following exhibits are filed with this report on Form 8-K:

 Exhibit
 Description of Exhibit

 99.1
 Press Release

#### Table of Contents

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## La Jolla Pharmaceutical Company

Date: March 11, 2004

By: /s/ Gail A. Sloan Gail A. Sloan Vice President of Finance and Controller

# Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

#### Table of Contents

# EXHIBIT INDEX

Exhibit Number

**Description of Exhibit** 

99.1 Press Release